Your browser is no longer supported. Please, upgrade your browser.
Settings
DMPI DelMar Pharmaceuticals, Inc. daily Stock Chart
DMPI [NASD]
DelMar Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.91 Insider Own0.10% Shs Outstand12.65M Perf Week-19.31%
Market Cap6.53M Forward P/E- EPS next Y-0.55 Insider Trans- Shs Float11.25M Perf Month-4.67%
Income-7.60M PEG- EPS next Q-0.13 Inst Own15.40% Short Float2.36% Perf Quarter-43.30%
Sales- P/S- EPS this Y41.80% Inst Trans-0.31% Short Ratio1.03 Perf Half Y-20.62%
Book/sh0.06 P/B8.60 EPS next Y16.90% ROA-142.80% Target Price3.00 Perf Year-84.46%
Cash/sh0.50 P/C1.04 EPS next 5Y- ROE610.20% 52W Range0.40 - 6.29 Perf YTD-25.18%
Dividend- P/FCF- EPS past 5Y-22.90% ROI- 52W High-92.35% Beta1.34
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin- 52W Low19.70% ATR0.05
Employees4 Current Ratio6.30 Sales Q/Q- Oper. Margin- RSI (14)35.59 Volatility9.28% 8.91%
OptionableNo Debt/Eq0.00 EPS Q/Q79.70% Profit Margin- Rel Volume0.96 Prev Close0.52
ShortableYes LT Debt/Eq0.00 EarningsFeb 10 AMC Payout- Avg Volume257.62K Price0.48
Recom2.00 SMA20-12.54% SMA50-16.66% SMA200-50.57% Volume246,182 Change-6.74%
Aug-14-17Downgrade Maxim Group Buy → Hold
Feb-19-20 08:00AM  DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors PR Newswire +5.67%
Feb-13-20 08:00AM  DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates PR Newswire
Feb-10-20 09:21AM  Will DelMar Pharmaceuticals (NASDAQ:DMPI) Spend Its Cash Wisely? Simply Wall St.
Feb-05-20 08:00AM  DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020 PR Newswire
Jan-29-20 08:00AM  DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme PR Newswire +8.94%
Dec-03-19 08:30AM  DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019 PR Newswire -5.69%
Nov-25-19 12:17PM  /C O R R E C T I O N -- DelMar Pharmaceuticals, Inc./ PR Newswire -13.32%
Nov-17-19 08:42AM  The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down Benzinga
Nov-14-19 08:00AM  DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates PR Newswire
Nov-11-19 09:52AM  Before You Buy DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI), Consider Its Volatility Simply Wall St. +5.11%
Nov-05-19 08:30AM  DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083 PR Newswire
Oct-29-19 08:30AM  DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting PR Newswire +10.57%
Oct-24-19 08:30AM  DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference PR Newswire
Oct-15-19 08:00AM  MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019 ACCESSWIRE
Oct-10-19 08:30AM  DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time PR Newswire
Sep-11-19 08:00AM  DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019 PR Newswire +5.79%
Sep-10-19 08:00AM  DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates PR Newswire
Sep-09-19 08:00AM  DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria PR Newswire
Sep-04-19 08:30AM  DelMar Pharmaceuticals Relocates Headquarters to San Diego, California PR Newswire
Aug-28-19 07:31AM  The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved Benzinga
Aug-27-19 11:42AM  A Look At Benzinga Pro's Most-Searched Tickers For August 27, 2019 Benzinga -15.66%
08:30AM  DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials PR Newswire
Aug-26-19 11:49AM  A Look At Benzinga Pro's Most-Searched Tickers For August 26, 2019 Benzinga
Aug-16-19 07:33AM  The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission Benzinga
Aug-14-19 09:10AM  DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering PR Newswire -40.47%
Aug-13-19 09:00AM  DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) PR Newswire -7.08%
Jul-31-19 08:00AM  DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) PR Newswire +5.95%
Jul-24-19 12:17PM  Here Is What's Driving The Rally In DelMar Pharmaceuticals Benzinga +20.89%
08:30AM  DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme PR Newswire
Jul-10-19 05:30AM  DelMar Announces Relocation of Company Headquarters to San Diego PR Newswire
Jun-27-19 07:26AM  The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO Benzinga +7.36%
05:30AM  Delmar Pharmaceuticals Announces Termination Of Rights Offering PR Newswire
Jun-25-19 05:28PM  DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019 PR Newswire -8.97%
Jun-11-19 05:30AM  Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering PR Newswire +5.85%
Jun-05-19 03:10PM  DelMar Pharmaceuticals Announces Closing of Financing PR Newswire
Jun-03-19 08:45AM  DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire -49.75%
08:30AM  DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering PR Newswire
May-29-19 09:00AM  DelMar Pharmaceuticals Updates Key Dates of Rights Offering PR Newswire -9.34%
May-23-19 02:30PM  DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE -19.35%
May-20-19 05:30AM  DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board PR Newswire -11.91%
May-15-19 05:30AM  DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results PR Newswire -17.54%
May-08-19 08:12AM  DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering PR Newswire -11.73%
May-07-19 04:53PM  DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split PR Newswire
Apr-04-19 05:30AM  DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board PR Newswire -7.78%
Apr-03-19 05:30AM  DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083 PR Newswire
Feb-20-19 05:30AM  DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM PR Newswire -13.62%
Feb-19-19 02:30PM  DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-12-19 05:30AM  DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results PR Newswire
Feb-07-19 05:30AM  DelMar Pharmaceuticals Receives Nasdaq Listing Extension PR Newswire
Nov-23-18 07:30AM  Consolidated Research: 2018 Summary Expectations for iKang Healthcare Group, Collectors Universe, QuickLogic, The Ultimate Software Group, Internet Gold Golden Lines, and DelMar Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-20-18 05:30AM  DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting PR Newswire
Nov-14-18 05:30AM  DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results PR Newswire
Oct-26-18 11:25AM  Treat Aurora Cannabis Stock Normally at Your Own Peril InvestorPlace
Oct-16-18 10:06AM  Who Owns Most Of DelMar Pharmaceuticals Inc (NASDAQ:DMPI)? Simply Wall St. +7.76%
Oct-10-18 05:30AM  DelMar Announces Further Validation of the Mechanism of Action of VAL-083 PR Newswire -6.15%
Sep-24-18 06:00AM  DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results PR Newswire
Sep-19-18 05:23PM  DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor PR Newswire +5.71%
Jun-26-18 06:00AM  DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM PR Newswire +5.93%
Jun-25-18 06:00AM  DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors PR Newswire -6.27%
May-30-18 07:50AM  Wired News Keryx Biopharmaceuticals Shares Results of Clinical Trial for Treating Patients with Advanced Chronic Kidney Disease with Ferric Citrate ACCESSWIRE
May-22-18 05:30AM  DelMar Appoints Saiid Zarrabian to Full-Time President and CEO PR Newswire
May-17-18 05:30AM  DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results PR Newswire
Apr-17-18 02:00PM  DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM PR Newswire
Apr-16-18 09:00AM  DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research PR Newswire
Feb-28-18 08:20AM  Todays Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals ACCESSWIRE
Feb-20-18 12:00PM  DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE -8.49%
Feb-14-18 05:39PM  DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results PR Newswire
03:19PM  Is DelMar Pharmaceuticals Inc (NASDAQ:DMPI) A Healthcare Industry Laggard Or Leader? Simply Wall St.
Dec-26-17 07:33AM  DelMar Pharmaceuticals' stock rockets after cancer treatment granted 'Fast Track' designation MarketWatch
05:30AM  DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma PR Newswire
Dec-08-17 01:33PM  Should You Be Concerned About DelMar Pharmaceuticals Incs (DMPI) Shareholders? Simply Wall St.
Nov-30-17 06:25PM  How Should You Think About DelMar Pharmaceuticals Incs (DMPI) Risks? Simply Wall St.
Nov-21-17 03:06PM  DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting PR Newswire
Nov-14-17 10:00AM  DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-13-17 06:14PM  DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results PR Newswire
Nov-07-17 04:05PM  DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer PR Newswire
Oct-31-17 05:30AM  DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer PR Newswire
Oct-24-17 12:17PM  ONCLIVE: Novel Alkylating Agent Defies Mechanisms of Resistance in GBM Tumors ACCESSWIRE
Oct-17-17 02:11PM  Is Now The Right Time To Invest In Healthcare And DelMar Pharmaceuticals Inc (DMPI)? Simply Wall St.
Oct-10-17 09:30AM  SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ACCESSWIRE
Oct-05-17 07:50AM  Earnings Review and Free Research Report: DelMar Missed Earnings Expectations ACCESSWIRE
Oct-04-17 11:00AM  Investor Network: DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-03-17 05:30AM  DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer PR Newswire
Sep-28-17 06:50PM  DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results PR Newswire
Sep-27-17 05:30AM  DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer PR Newswire
Sep-26-17 10:00AM  CEO Jeffery Bacha Discusses DelMars VOL-083 Clinical Trials and the Major Milestones Ahead GlobeNewswire
Sep-22-17 02:20PM  DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market PR Newswire
Sep-21-17 08:00AM  Today's Research Reports on Trending Tickers: DelMar Pharmaceuticals and Ionis Pharmaceuticals ACCESSWIRE
Sep-20-17 03:31PM  DelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market PR Newswire
05:30AM  DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083 PR Newswire
Sep-18-17 08:00AM  DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer PR Newswire
Sep-11-17 04:00AM  DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme PR Newswire
Sep-06-17 01:58PM  DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017 PR Newswire
Jul-24-17 08:30AM  DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM PR Newswire
Jul-18-17 08:30AM  DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM PR Newswire
Jul-11-17 08:30AM  DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman PR Newswire
Jun-29-17 08:30AM  DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable PR Newswire
Jun-22-17 08:30AM  DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM PR Newswire
Jun-16-17 08:30AM  DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference PR Newswire
May-18-17 05:13PM  DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results PR Newswire
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.